The HALT polycystic kidney disease trials: Design and implementation

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 1, 2010, Pages 102-109

  Chapman, Arlene B ^a   Torres, Vicente E ^b   Perrone, Ronald D ^c   Steinman, Theodore I ^d   Bae, Kyongtae T ^e   Philip Miller, J ^f   Miskulin, Dana C ^c   Oskoui, Frederic Rahbari ^a   Masoumi, Amirali ^g   Hogan, Marie C ^a   Winklhofer, Franz T ^h   Braun, William ⁱ   Thompson, Paul A ^j   Meyers, Catherine M ^k   Kelleher, Cass ^g   Schrier, Robert W ^g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g University of Colorado   (United States)

^h UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF SOUTH DAKOTA   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOPROLOL; MINOXIDIL; TELMISARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; PATIENT SAFETY; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 75749109803     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04310709     Document Type: Article

References (46)

1. U.S. Renal Data System: Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
2. Parfrey PS, Bear JC, Morgan J, Cramer BC, McManamon PJ, Gault MH, Churchill DN, Singh M, Hewitt R, Somlo S, et al: The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 323: 1085-1090, 1990
3. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41: 1311-1319, 1992
4. Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 5: 2037-2047, 1995
5. Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH: Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26: 190-193, 1984
6. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
7. Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 1: 148-157, 2006
8. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wuthrich RP, Serra AL: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75: 235-241, 2009
9. Chapman A, Grantham JJ, Guay-Woodford LM, Torres VE, Bae KT, Miller JP, Meyers, CM: Progression of Renal Disease in Hypertensive (HBP) ADPKD Subjects Utilizing MR: The CRISP Consortium. J Am Soc Nephrol 16: 359A, 2005
10. Schrier RW: Renal volume, renin-angiotesin-aldosterone system, hypertension and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20: 1888-1893, 2009
11. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN, Carretero OA, Inagami T, McAteer JA, Johnson CM: Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 42: 364-373, 1992
12. Torres VE, Wilson DM, Burnett JC Jr, Johnson CM, Offord KP: Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 66: 1010-1017, 1991
13. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323: 1091-1096, 1990
14. Doulton TW, Saggar-Malik AK, He FJ, Carney C, Markandu ND, Sagnella GA, MacGregor GA: The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 24: 939-945, 2006
15. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996
16. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
17. Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T: Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99: c18-c23, 2005
18. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 13: 1733-1739, 2002
19. Jafar T, Stark P, Schmid C, Strandgaard S, Kamper A, Maschio G, Becker G, Perrone RD, Levey AS, ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group: The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 67: 265-271, 2005
20. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD: Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 573-579, 2008
21. Watson ML, Macnicol AM, Allan PL, Wright AF: Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 41: 206-210, 1992
22. van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RG: No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 18: 2314-2320, 2003
23. McPherson EA, Luo Z, Brown RA, LeBard LS, Corless CC, Speth RC, Bagby SP: Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 15: 493-500, 2004
24. Stepniakowski KT, Gerron GG, Chapman AB: Dissociation between systemic, adrenal, and renal response to angiotensin converting enzyme inhibition (Enalapril (En) 20 mg/ day), angiotensin receptor blocker (Losartan (Los) 50 mg/ day) vs combination therapy (En/Los) in subjects with autosomal dominant polycystic kidney disease (PKD) during equimolar intravenous angiotensin I (Ang I) and angiotensin II (Ang II) infusion. J Am Soc Nephrol 13: 507a-508a, 2002
25. Stepniakowski KT, Gerron GG, Chapman AB: Basal systemic, adrenal and renal responses to angiotensin converting enzyme inhibitor (Enalapirl (En) 20 mg), angiotensin receptor blocker (Losartan (Los) 50 mg) vs. combination therapy in autosomal dominant polycystic kidney disease (PKD). J Am Soc Nephrol 13: 508a, 2002
26. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343: 824-827, 1994
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572, 2003
28. Levey A, Greene T, Kusek JW, Beck, GJ: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11: 155A, 2000
29. Walser, M: Creatinine excretion as a measure of protein nutrition in adults of varying age. J Parenter Enteral Nutr 11: 73S-78S, 1987
30. King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP: Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 64: 2214-2221, 2003
31. Moore SM, Maffitt DR, Blaine GJ, Bae KT: Workstation acquisition node for multicenter imaging studies. In: Medical Imaging 2001: PACS and Integrated Medical Information Systems: Design and Evaluation, edited by Siegel EL, Huang HK, San Diego, International Society of Optical Engineering, 2001, pp 271-277
32. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18: 2143-2160, 2007
33. Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LJ, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC: Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int 74: 1468-1479, 2008
34. Prentice RL, Williams J, Peterson AV: On the regression analysis of multivariate failure time data. Biometrika 68: 373-379, 1981
35. Seber GAF, Wild CJ: Nonlinear Regression, New York, John Wiley & Sons, 1989
36. Anderson PK, Gill RD: Cox's regression model for counting processes: A large sample study. Ann Stat 10: 1100-1120, 1982
37. Ryan MJ, Tuttle KR: Elevations in serum creatinine with RAAS blockade: Why isn't it a sign of kidney injury? Curr Opin Nephrol Hypertens 17: 443-449, 2008
38. Lan KK, DeMets DL: Changing frequency of interim analysis in sequential monitoring. Biometrics 45: 1017-1020, 1989
39. Lefante JJ: The power to detect differences in average rates of change in longitudinal studies. Stat Med 9: 437-446, 1990
40. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 38: 963-974, 1982
41. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
42. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003
43. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48, 2008
44. Kunz R, Wolbers M, Glass T, Mann JF: The COOPERATE trial: A letter of concern. Lancet 371: 1575-1576, 2008
45. Halimi JM, Mimran A: ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? Curr Hypertens Rep 11: 85-87, 2009
46. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, Weishaupt D, Tschirch F: Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8: 13, 2007